Rahul Kakkar, Tome Biosciences CEO
MIT gene editing spinout launches with $213M to write the 'final chapter in genomic medicine'
When John Finn agreed to meet two young MIT scientists in the summer of 2021, they explained how they had developed a twist on CRISPR …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
